CA2271799A1 - Compositions de traitement de troubles gastro-intestinaux contenant du bismuth, des anti-inflammatoires non steroidiens ainsi qu'un ou plusieurs agents anti-microbiens et methodescorrespondantes - Google Patents

Compositions de traitement de troubles gastro-intestinaux contenant du bismuth, des anti-inflammatoires non steroidiens ainsi qu'un ou plusieurs agents anti-microbiens et methodescorrespondantes Download PDF

Info

Publication number
CA2271799A1
CA2271799A1 CA002271799A CA2271799A CA2271799A1 CA 2271799 A1 CA2271799 A1 CA 2271799A1 CA 002271799 A CA002271799 A CA 002271799A CA 2271799 A CA2271799 A CA 2271799A CA 2271799 A1 CA2271799 A1 CA 2271799A1
Authority
CA
Canada
Prior art keywords
bismuth
days
milligrams
composition
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002271799A
Other languages
English (en)
Inventor
Jonathan Davidson Kaunitz
Owen Rickford Carryl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of CA2271799A1 publication Critical patent/CA2271799A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des méthodes et des compositions pour traiter les troubles gastro-intestinaux provoqués par Helicobacter pylori, contenant du bismuth, une quantité gastropathique d'un médicament anti-inflammatoire non stéroïdien et une quantité suffisante pour avoir un effet thérapeutique d'un ou de plusieurs anti-microbiens. La composition peut également contenir une quantité suffisante pour avoir un effet thérapeutique, d'un ou de plusieurs médicaments anti-sécrétoires.
CA002271799A 1996-11-22 1997-11-21 Compositions de traitement de troubles gastro-intestinaux contenant du bismuth, des anti-inflammatoires non steroidiens ainsi qu'un ou plusieurs agents anti-microbiens et methodescorrespondantes Abandoned CA2271799A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75551896A 1996-11-22 1996-11-22
US08/755,518 1996-11-22
PCT/US1997/021461 WO1998022117A1 (fr) 1996-11-22 1997-11-21 Compositions de traitement de troubles gastro-intestinaux contenant du bismuth, des anti-inflammatoires non steroidiens ainsi qu'un ou plusieurs agents anti-microbiens et methodes correspondantes

Publications (1)

Publication Number Publication Date
CA2271799A1 true CA2271799A1 (fr) 1998-05-28

Family

ID=25039486

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002271799A Abandoned CA2271799A1 (fr) 1996-11-22 1997-11-21 Compositions de traitement de troubles gastro-intestinaux contenant du bismuth, des anti-inflammatoires non steroidiens ainsi qu'un ou plusieurs agents anti-microbiens et methodescorrespondantes

Country Status (4)

Country Link
EP (1) EP0941101A1 (fr)
CA (1) CA2271799A1 (fr)
NO (1) NO992469L (fr)
WO (1) WO1998022117A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
WO1999010000A1 (fr) * 1997-08-25 1999-03-04 The Procter & Gamble Company Preparations combinees pour le traitement des douleurs du tractus gastro-intestinal superieur
IL145220A0 (en) * 1999-05-20 2002-06-30 Par Pharmaceutical Inc Stabilized composition based on pyridinyl-sulfinyl-benzimidazoles and process
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
IL142037A0 (en) * 2001-03-15 2002-03-10 Agis Ind 1983 Ltd Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
EP2260837A1 (fr) 2001-06-01 2010-12-15 Pozen, Inc. Compositions pharmaceutiques pour l'administration coordonnée d'AINS
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
JP5035865B2 (ja) * 2005-09-26 2012-09-26 国立大学法人高知大学 Ｈｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉ菌株の増殖・運動抑制方法
BRPI0918492A2 (pt) 2008-09-09 2015-12-01 Astrazeneca Ab uso de naproxen, ou sal farmaceuticamente aceitável do mesmo, e esomeprazol, ou sal farmaceuticamente aceitável do mesmo
EP2445499A4 (fr) 2009-06-25 2013-02-27 Astrazeneca Ab Procede pour le traitement d'un patient a risque de developer un ulcere associe a nsaid
UA115139C2 (uk) 2011-12-28 2017-09-25 Поузен Інк. Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
ES2744406T3 (es) 2013-02-13 2020-02-25 Redhill Biopharma Ltd Composiciones farmacéuticas para el tratamiento de helicobacter pylori
WO2017125912A1 (fr) * 2016-01-21 2017-07-27 Dexcel Pharma Technologies Ltd. Méthodes permettant de traiter une infection à helicobacter
US11878011B2 (en) 2020-05-07 2024-01-23 Redhill Biopharma Ltd. Method for eradicating Helicobacter pylori infection in patients regardless of body mass index

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI910088A7 (fi) * 1990-01-09 1991-07-10 Brocades Pharma Bv Oraalinen farmaseuttinen koostumus
DE69228738D1 (de) * 1991-12-06 1999-04-29 Glaxo Group Ltd Zusammensetzungen zur Behandlung von entzündlichen Zuständen oder Analgesie, die Ranitidin Wismuth Citrat und einen NSAID enthalten

Also Published As

Publication number Publication date
NO992469D0 (no) 1999-05-21
WO1998022117A1 (fr) 1998-05-28
EP0941101A1 (fr) 1999-09-15
NO992469L (no) 1999-07-22

Similar Documents

Publication Publication Date Title
CA2271799A1 (fr) Compositions de traitement de troubles gastro-intestinaux contenant du bismuth, des anti-inflammatoires non steroidiens ainsi qu'un ou plusieurs agents anti-microbiens et methodescorrespondantes
EP0941102A1 (fr) Compositions et methodes pour traiter des troubles gastro-intestinaux
JPH0794390B2 (ja) 胃腸疾患の治療のための医薬組成物
JP2648327B2 (ja) 胃腸疾患を治療するための組成物及び方法
JP2648328B2 (ja) 胃腸疾患を治療するための組成物及び方法
JP5908569B2 (ja) 胃腸疾患を治療するための方法
JP6366548B2 (ja) 胃酸分泌の即効性阻害剤
Hosking et al. Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial
IE59584B1 (en) Use of bismuth for the manufacture of a medicament for the treatment of gastrointestinal disorders induced by campylobacter pyloridis
US4940695A (en) Bismuth-containing pharmaceutical compositions
US5447923A (en) Methods and compositions of diphenyl ether phosphate esters for the treatment of gastrointestinal disorders
Holle Pathophysiology and modern treatment of ulcer disease
Rahman et al. Association between Helicobacter pylori infection and iron deficiency anemia: a cross sectional study
Clearfield Helicobacter pylori: aggressor or innocent bystander?
JP3288550B2 (ja) ヘリコバクター・ピロリ菌殺菌のための局所用口腔内投与剤
WO1996024342A1 (fr) Traitement concomitant a base de composes au bismuth par voie orale
JP2000507572A (ja) 胃炎、逆流食道炎、十二指腸炎、消化不良および潰瘍の治療用調合薬品
Hunt Helicobacter pylori eradication: a critical appraisal and current concerns
Fraser et al. Effect of ranitidine bismuth citrate on postprandial plasma gastrin and pepsinogens.
CA2239420C (fr) Compositions destinees a la prevention et au traitement de troubles gastro-intestinaux et comprenant du bismuth ainsi qu'un ou plusieurs agents antimicrobiens
Kolkman et al. Ranitidine bismuth citrate with clarithromycin versus omeprazole with amoxycillin in the cure of Helicobacter pylori infection
Dahlgren et al. Organobismuth compounds: activity against Helicobacter pylori
Shimoyama et al. Eradication of Helicobacter pylori with Lansoprazole and Clarithromycin
Moore et al. The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment
Luman et al. One week triple therapy for Helicobacter pylori associated duodenal ulcer disease

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued